(TheNewswire)
Toronto, Ontario / TheNewswire / August 8,
2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to present an
update on its progress to provide better tools for cardiac analysis to cardiologists to improve diagnosis and treatment of heart
disease.
Product Development
Hardware upgrades to lower cost and improve usability : The Company previously announced
(see NR, Nov 11, 2017) the invention of a small, low-cost device that attaches to, or is encased in, any hand-held
ultrasound probe and tracks the probe’s position and orientation in 3-dimensional space. The Company is pleased to report
that it has used this technology to build a prototype of the next-generation VMS+ heart analysis system. This new device
(VMS+ 3.0) is undergoing final testing and development to verify its performance. The new design eliminates the need for
patients to remain motionless during image acquisition and improves the workflow of the VMS+ through a more intuitive user
interface. The VMS+ 3.0 also will allow the Company to provide the VMS+ inexpensively to customers and charge for the
reconstruction of the study. This subscription model is the trend in imaging studies as it becomes more cost effective to
outsource the analysis than to maintain the expertise to analyze difficult and technically-challenging cases, especially in small
and medium-sized centres. The Company intends to offer both a capital purchase as well as the subscription option to
customers starting in 2019.
New Intellectual Property (IP) : The Company has been working to build a
robust IP portfolio. A provisional patent application was filed with the United States Patent and Trademark Office. The
invention relates to a small handheld diagnostic image system that incorporates one or more position sensors to collect position
data with the diagnostic image data of an organ. The position data is associated with the diagnostic image data to identify
reference points in the organ to construct a three-dimensional model of the organ including measurement data. This
invention is aimed at the point-of-care market where ultrasound is viewed on smart phones or other smaller devices. The invention
embodies a way to rapidly analyze these images which would allow for correct interpretations of the data. The use of POC
ultrasound is the trend in medical imaging as better handheld system become available.
Annual General Meeting
The Company will hold its Annual General Meeting on August 13 th at its corporate
offices in Toronto. The prototype of the new VMS+ 3.0 will be available for viewing. More details are included in the
circular, which has been mailed to shareholders of record.
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based
Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the
first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has
developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac
care.
For further information please contact:
Dr. George Adams, CEO, Telephone: (519) 803-6937
Email: gadams@ventripoint.com
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of
applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing",
"may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking
information or statements. The forward-looking statements and information are based on certain key expectations and assumptions
made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking
statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and
information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking
statements and information address future events and conditions, by their very nature they involve inherent risks and
uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other
factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most
recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR at www.sedar.com.
Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news
release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news
release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any
forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required
by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright (c) 2018 TheNewswire - All rights reserved.